Case control study of clinical malaria
OtherCase control study of clinical malaria
NCT Number: NCT07009847
This is an observational case-control study to assess the effectiveness of the R21/Matrix-M vaccine against severe malaria, clinical malaria (in high transmission perennial areas), and to assess if the R21 vaccine recipients are at an increased risk of deaths (all-cause). Clinical malaria, severe malaria and death (all-cause) cases will be enrolled in study. For each case (severe or death) 4 controls matched for age and neighborhood will be enrolled whereas for clinical malaria case, 1 matched control will be enrolled.
1. Proportion of vaccinated and unvaccinated children amongst Severe Malaria Cases caused by P. falciparum. 2. Proportion of vaccinated and unvaccinated children amongst Clinical Malaria Cases in high-transmission perennial areas caused by P. falciparum. 3. Proportion of vaccinated and unvaccinated children in cases of death (all cause) 4. Exploratory effectiveness endpoint: Proportion of vaccinated and unvaccinated children in the hospitalized clinical and severe malaria cases.
Interested in participating?
Request Info5 month and older
All sexes
Observational
Unité de Recherche Clinique de Nanoro (URCN), Institut de Recherche en Sciences de la Santé, Direction Régionale du Centre-Ouest (IRSS-DRCO), Bousse, Bousse, Burkina Faso
The study will be conducted at multiple centers with the appropriate research infrastructure to carry out safety and/or effectiveness research across different countries where the R21/Matrix-M vaccine is (or will be) approved and deployed for vaccination with subsequent population uptake.
The cases will be enrolled from hospitals/clinics and the matched controls will be recruited from the community by visiting the neighborhood.
Children eligible for receiving R21/Matrix-M vaccine, residing in the geographical area where the vaccine has been deployed will be considered as either cases or controls if they meet the eligibility criteria. All participants will be screened for eligibility after obtaining informed written consent from parents/legal guardians/ caregivers.
Surveillance and detection of cases: Cases qualifying the case definitions of clinical or severe malaria, cases will be recruited from the hospitals, clinics or the sub-sites.
For deaths, cases will be recruited from the hospital or the community. Cause of death will be ascertained from hospital or available medical records as well as discussions with family or healthcare professionals who may have been involved.
Identification of controls: Four controls for each case will be recruited by study physician or field staff from community for severe malaria and death cases. For clinical malaria cases in high-transmission perennial areas, case: control ratio will be 1:1. Controls will be matched for age and neighborhood. Controls should be residing in the same neighborhood as the respective case, but not from the same house. Living controls will be enrolled against the death cases. Vaccination status will be confirmed from the vaccination/immunization cards, hospital/clinic records, home based registers, or national immunization database. History from the parents/ guardians/ caregivers will be considered in case of non-vaccination. Field staff may visit the homes of controls and (if required) cases for collection of the required data.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
For Cases- A male or female child eligible to have received R21/Matrix-M Vaccine based on age. 2 Parent/legal guardian/ caregiver of the child willing to provide the written informed consent for their child's participation in the study.
3 Parent/legal guardian/ caregiver willing to comply with the study requirements and share or allow access to the data regarding the vaccination status and medical records with the study personnel.
4 Resident of the R21/Matrix-M vaccine implementation area and brought to the study hospital /clinic or sub-site with clinical complaints. 5 Child meeting the respective case definition (Severe Malaria, Clinical Malaria or Death due to any cause).
For Controls- A male or female child eligible to have received R21/Matrix-M Vaccine based on age. The matched control should have a date of birth within 60 days of that of the case.
Exclusion criteria
For Cases-
For Controls-
Case control study of clinical malaria
Case control study of severe malaria
Case control study of death (all cause)
Time frame: through study, an average of one year
Proportion of vaccinated and unvaccinated children amongst Severe Malaria Cases caused by P. falciparum.
Time frame: through study, an average of one year
Proportion of vaccinated and unvaccinated children amongst Clinical Malaria Cases caused by P. falciparum.
Time frame: through study, an average of one year
Proportion of vaccinated and unvaccinated children in cases of death
Contact information is provided by the study sponsor or research team.
Dr. Prasad Kulkarni, MD, FRCP
CONTACT
Dr. Sandesh M Bharati, MD
CONTACT
Serum Institute of India Pvt. Ltd.
Industry
A Case Control Study to Assess Effectiveness and Safety of The R21/Matrix-M Malaria Vaccine
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05978037
Infections, Malaria
Oxford, Oxfordshire, United Kingdom
View Trial DetailsNCT06558643
Infections, Malaria
Ruddington, Nottingham, United Kingdom
View Trial DetailsNCT05567016
Asymptomatic Diseases, Asymptomatic Infections
Bagamoyo, Tanzania
View Trial DetailsNCT05979207
Anti-Infective Agents, Antimalarials
Brisbane, Queensland, Australia
View Trial Details